Budesonide Shows COVID-19 Promise: Should It Be Evaluated In India?

UK studies indicate the potential of inhaled budesonide in improving COVID-19 recovery time in specific groups, with some leading Indian physicians suggesting that the widely available asthma/COPD therapy should be selectively evaluated in the Indian context as well.

Potential For Wider Use Of Budesonide For COVID-19? • Source: Alamy

Leading physicians in India appear to be generally backing wider but appropriate use of inhaled budesonide following promising data from the UK on use of the glucocorticoid in improving COVID-19 treatment outcomes.

The UK’s Platform Randomised Trial of Interventions against COVID-19 in Older People (PRINCIPLE) trial recently indicated that the commonly used asthma therapy could shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from COVID-19

More from Scrip

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By 

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.